NeueHealth 대차 대조표 상태

재무 상태 기준 확인 0/6

NeueHealth 의 총 주주 지분은 $-312.5M 이고 총 부채는 $120.3M, 이는 부채 대 자기자본 비율을 -38.5% 로 가져옵니다. 총자산과 총부채는 각각 $696.8M 및 $1.0B 입니다.

주요 정보

-38.5%

부채 비율

US$120.25m

부채

이자 보상 비율	n/a
현금	US$118.68m
주식	-US$312.52m
총 부채	US$1.01b
총 자산	US$696.78m

최근 재무 상태 업데이트

Recent updates

Bright Health narrows footprint to only offer Medicare Advantage in California, Florida

Oct 11

Analysts Have Been Trimming Their Bright Health Group, Inc. (NYSE:BHG) Price Target After Its Latest Report

Aug 13

Bright Health Group Takes Cost Actions To Effect Turnaround

Jul 21

Bright Health Group: Examining A Dumpster Fire

Jan 04

재무 상태 분석

단기부채: NEUE 에는 음의 주주 지분이 있는데, 이는 단기 부채를 감당하지 못하는 단기 자산보다 더 심각한 상황입니다.

장기 부채: NEUE 의 주주 지분은 음수입니다. 이는 장기 부채를 감당하지 못하는 단기 자산보다 더 심각한 상황입니다.

부채 대 자본 내역 및 분석

부채 수준: NEUE 은 부정주주자본을 갖고 있는데, 이는 높은 부채 수준보다 더 심각한 상황입니다.

부채 감소: NEUE 의 주주 지분은 음수이므로 시간이 지남에 따라 부채가 감소했는지 확인할 필요가 없습니다.

부채 범위: NEUE 의 영업현금흐름이 마이너스이므로 부채가 제대로 상환되지 않습니다.

이자 보장: NEUE 의 부채에 대한 이자 지급이 EBIT에 의해 잘 충당되었는지 판단할 데이터가 부족합니다.

NeueHealth 대차 대조표 상태

재무 상태 기준 확인 0/6

주요 정보

최근 재무 상태 업데이트

Bright Health Group Receives Continued Listing Standard Notice from NYSE

Recent updates

Third quarter 2024 earnings released: US$6.78 loss per share (vs US$72.52 loss in 3Q 2023)

NeueHealth, Inc. Reaffirms Earnings Guidance for the Year 2024

NeueHealth, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Insufficient new directors

Second quarter 2024 earnings released: US$6.42 loss per share (vs US$8.55 loss in 2Q 2023)

NeueHealth, Inc. Updates Earnings Guidance for the Year 2024

NeueHealth, Inc. to Report Q2, 2024 Results on Aug 07, 2024

New major risk - Financial position

NeueHealth, Inc. announced that it has received $150 million in funding

New minor risk - Shareholder dilution

NeueHealth, Inc. Reaffirms Earnings Guidance for the Year 2024

First quarter 2024 earnings released: US$2.31 loss per share (vs US$9.04 loss in 1Q 2023)

NeueHealth, Inc. to Report Q1, 2024 Results on May 08, 2024

NeueHealth, Inc., Annual General Meeting, May 02, 2024

Vice Chairman recently sold US$59k worth of stock

New minor risk - Shareholder dilution

New major risk - Negative shareholders equity

Full year 2023 earnings released: US$70.72 loss per share (vs US$98.28 loss in FY 2022)

NeueHealth, Inc. Provides Earnings Guidance for the Year 2024

NeueHealth, Inc. to Report Q4, 2023 Results on Mar 06, 2024

Third quarter 2023 earnings released: US$72.52 loss per share (vs US$40.11 loss in 3Q 2022)

Bright Health Group, Inc. Provides Earnings Guidance for the Full Year 2023

New major risk - Revenue and earnings growth

Bright Health Group, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Bright Health Group, Inc. Announces Leaving of Jeff Cook as Chief Operating Officer, Effective October 13, 2023

Consensus EPS estimates upgraded to US$51.32 loss

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Bright Health Group, Inc. Revises Its Financial Outlook for 2023

Bright Health Group, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Price target increased by 47% to US$200

Florence Labs, Inc. acquired Zipnosis, Inc. from Bright Health Group, Inc. (NYSE:BHG).

Price target decreased by 14% to US$1.70

Bright Health Group, Inc. Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Bright Health Group Announces Chief Financial Officer Changes

Vice Chairman recently sold US$158k worth of stock

Price target decreased by 24% to US$1.50

Consensus EPS estimates fall by 14%

Full year 2022 earnings released: US$1.23 loss per share (vs US$3.02 loss in FY 2021)

Bright Health Group, Inc. to Report Q4, 2022 Results on Mar 01, 2023

Bright Health Group: Stock Price Has Been Too Heavily Beaten Down

Bright Health Group expects FY23 revenue to be below consensus

Independent Director recently bought US$248k worth of stock

Bright Health Group Receives Continued Listing Standard Notice from NYSE

Bright Health receives non-compliance notice from NYSE

Independent Lead Director recently bought US$294k worth of stock

Price target decreased to US$2.07

High number of new directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Bright Health Group, Inc. Reports Goodwill Impairment for the Three Months Ended September 30, 2022

Bright Health Group reports Q3 mixed earnings; revises Fy22 guidance

Bright Health Group, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Bright Health Group, Inc. announced that it has received $175 million in funding from a group of investors

Bright Health Group, Inc. Provides Revenue Guidance for the Year 2023

Bright Health narrows footprint to only offer Medicare Advantage in California, Florida

Analysts Have Been Trimming Their Bright Health Group, Inc. (NYSE:BHG) Price Target After Its Latest Report

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Bright Health Group, Inc. Provides Revenue Guidance for the Full Year 2022

Bright Health Group, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Bright Health Group Takes Cost Actions To Effect Turnaround

Price target decreased to US$2.76

Bright Health Group, Inc.(NYSE:BHG) dropped from Russell 2000 Growth Index

Bright Health Group Expands Executive Team as It Drives Performance in Scaled Businesses

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

Bright Health Group, Inc. to Report Q1, 2022 Results on May 04, 2022

Bright Health Group, Inc., Annual General Meeting, May 13, 2022

Consensus forecasts updated

Bright Health Group, Inc. Provides Earnings Guidance for the Year 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Bright Health Group, Inc. Provides Earnings Guidance for the Year 2022

Bright Health Group, Inc. to Report Q4, 2021 Results on Mar 02, 2022

Bright Health Group Announces Executive Changes, Effective March 11, 2022